ÖSSUR/OTTOBOCK
25.1.2016 20:00:10 CET | Business Wire | Press release
Össur and Ottobock, two of the world’s leading prosthetics innovators, will undertake a historic joint philanthropic effort to further development in the breakthrough field of mind-controlled prosthetics, it was announced today.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160125006380/en/
Fueled by the companies’ initial combined contribution of US$1 million, the Össur and Ottobock Research Trust Fund that has been established at the University of Iceland will award international grants for scientific research and innovative projects in the field of advanced neural control of prosthetic limbs.
“Neural-controlled prosthetics is one of the greatest clinical challenges in our field, and its potential to impact lives is so significant that both companies embraced the opportunity to marshal resources and help accelerate this critical technological development,” said Thorvaldur Ingvarsson, M.D., Ph.D., Executive Vice President of Research and Development of Össur.
“Neural-controlled prosthetics could transform the lives of thousands of people with limb loss throughout the world, and we look forward to supporting the ongoing exploration of the field through the creation of this new fund,” said Dr. Hans Dietl, Chief Technology Officer of Ottobock.
The first grants from the Össur and Ottobock Research Fund at the University of Iceland will be rewarded within one year. The fund will be governed by a four-person committee, comprised of two University of Iceland representatives and one representative from each company.
“We are gratified that our University has been chosen to play a pivotal role in furthering mind-controlled prosthetics technology,” said Dr. Jón Atli Benediktsson, Rector of the University of Iceland. According to Dr. Benediktsson, details regarding the Fund’s grant application process will be announced in the near future.
About Össur
Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people’s mobility through the delivery of innovative technologies within the fields of Prosthetic, Osteoarthritis and Injury Solutions. A recognized “Technology Pioneer,” Össur invests significantly in research and product development—its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com
About Ottobock
Around the world, the Ottobock name stands for high-quality and technologically outstanding products and services. The goal of helping to restore mobility for people - or protect what mobility they have - stands behind each and every Ottobock product. The conviction that quality of life is closely associated with a maximum of individual freedom and independence is a key concept that has been a major influence throughout the company’s history. Since its founding in Berlin in 1919, Ottobock has pursued a vision: to improve the mobility of people with disabilities through innovative products. In doing so, the company equates quality with “Quality for life”: the quality of life enjoyed by the people who use Ottobock products every day. www.ottobock.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160125006380/en/
Contact:
For ÖSSUR:
Laura Jackson, +1-714-745-9526
lauraminjackson@gmail.com
or
For
OTTOBOCK:
Rüdiger Herzog, +49 5527 848 1859
ruediger.herzog@ottobock.de
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release
New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations
Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win30.6.2026 15:00:00 CEST | Press release
New configuration-aware commercial intelligence capability connects customer requirements, configuration decisions, and business outcomes to optimize win rates, margin and product strategy. Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes. Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them. ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear
SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 15:00:00 CEST | Press release
First-in-class disease-modifying therapeutic aerosol targeting mechano-sensitive ion channels advances into phase 2 clinical evaluation in UK SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hyper
Riskified Study: As AI Drives a Summer Travel Boom, Clunky Security and Scam Fears Threaten Merchant Conversions30.6.2026 14:30:00 CEST | Press release
New 2026 Summer Travel Survey from Riskified finds that digital and AI tools are reshaping how trips are planned, while security and authenticity concerns continue to influence checkout decisions Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released findings from global survey conducted ahead of the 2026 Summer Travel season, exploring consumer travel behavior, booking experiences, and trust in digital and AI-enabled travel tools. The survey, conducted among more than 4,000 consumers across the United States, United Kingdom, China, Japan, Mexico, Brazil, and Colombia, shows strong demand for travel heading into the summer season, alongside continued adoption of digital and AI tools in trip planning. Key findings from the Riskified 2026 Summer Travel Survey include: 81% of consumers use digital platforms for travel planning, with 26% already relying on AI like ChatGPT or Gemini. Leisure remains the dominant purpose of travel at 63%, followed by
Corpay Cross-Border Named the Official Global FX Partner of Fever30.6.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, today announced that its Cross-Border business has entered into an agreement with Fever, a leading global live-entertainment discovery and ticketing platform that specializes in immersive experiences, candlelit concerts, and interactive pop-up events. Under the agreement, Corpay becomes Fever’s exclusive and Official Global Foreign Exchange (FX) Partner. Through this partnership, Fever’s global operations across North America, Mexico, the UK, EMEA, and APAC will be able to leverage Corpay Cross-Border’s innovative solutions to help manage foreign exchange exposure arising from day-to-day business activities. “Fever represents the future of global live entertainment and event ticketing technology, and we are honoured to be named their exclusive and Official FX Partner,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom